Condition
ER Positive, HER2 Negative Breast Cancer
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
3 treatments under study, led by Letrozole Pd 0332991
Research Leaders
5 sponsors active, led by Organisation for Oncology and Translational Research
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Phase 2 (2)
Trial Status
Recruiting1
Unknown1
Clinical Trials (2)
Research Network
Common Treatments
- Letrozole Pd 03329911
- Tocilizumabtocilizumab Biosimilar1
- Soc Chemotherapy1
Active Sponsors
- Organisation for Oncology and Translational Research1
- Genentech, Inc.1
- Kathy Miller1
- Breast Cancer Research Foundation1
- Susan G. Komen Breast Cancer Foundation1
Top Investigators
Indiana University
Related Conditions
- Estrogenreceptorlow Breast Cancer1
- Triple Negative Breast Cancer1
- Metastatic Breast Cancer1